(Q44761920)

6 December 2017

title

Prognostic and therapeutic considerations in clinical primary pulmonary hypertension (English)

1 reference

6 December 2017

Chapman PJ

1

1 reference

6 December 2017

Bateman ED

series ordinal

2

1 reference

6 December 2017

Benatar SR

series ordinal

3

1 reference

6 December 2017

language of work or name

1 reference

1 November 1990

1 reference

6 December 2017

1 reference

6 December 2017

volume

84

1 reference

6 December 2017

issue

6

1 reference

6 December 2017

page(s)

489-494

1 reference

Primary pulmonary hypertension. Review of clinical features and pathologic physiology with a report of pulmonary hemodynamics derived from repeated catheterization

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Factors that influence the outcome of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Primary pulmonary hypertension: natural history and the importance of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Clinical primary pulmonary hypertension: three pathologic types

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Primary pulmonary hypertension. I. Clinical and hemodynamic study

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Reversibility of primary pulmonary hypertension during six years of treatment with oral diazoxide

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin)

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

The role of hydralazine therapy for pulmonary arterial hypertension of unknown cause.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Acute hemodynamic effects of nitroglycerin in pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Diazoxide in treatment of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Pulmonary function in advanced pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Restrictive ventilatory pattern in precapillary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Hazards of diazoxide in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Vasodilator therapy in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Diazoxide in treatment of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Primary pulmonary hypertension: effects of nifedipine

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Oral hydralazine therapy for primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Vasodilators and primary pulmonary hypertension. Variability of long-term response

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

The kingdom of the near-dead. The shortened unnatural life history of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2808%2980114-X

7 January 2021

10.1016/S0954-6111(08)80114-X

Identifiers

DOI

1 reference

release_6mmhf2dubbdtzcqvgi7fp5rzke

6 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6mmhf2dubbdtzcqvgi7fp5rzke

24 November 2022

mapped directly with Wikidata item

1 reference